XTX Topco Ltd Buys 12,975 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

XTX Topco Ltd boosted its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) by 76.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,013 shares of the biopharmaceutical company’s stock after acquiring an additional 12,975 shares during the period. XTX Topco Ltd’s holdings in Arbutus Biopharma were worth $116,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in shares of Arbutus Biopharma during the second quarter valued at approximately $34,000. Helen Stephens Group LLC bought a new stake in Arbutus Biopharma in the 3rd quarter valued at $50,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Arbutus Biopharma by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 36,309 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 14,138 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Arbutus Biopharma during the 3rd quarter worth about $142,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Arbutus Biopharma by 453.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 30,723 shares in the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

Arbutus Biopharma Stock Performance

Shares of ABUS opened at $3.21 on Friday. The stock has a fifty day moving average price of $3.71 and a two-hundred day moving average price of $3.70. The company has a market cap of $608.27 million, a price-to-earnings ratio of -7.46 and a beta of 1.84. Arbutus Biopharma Co. has a 52-week low of $2.21 and a 52-week high of $4.72.

Analyst Upgrades and Downgrades

ABUS has been the topic of a number of recent research reports. Chardan Capital reaffirmed a “buy” rating and set a $5.00 price objective (up from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. Jefferies Financial Group upped their price target on Arbutus Biopharma from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. JMP Securities lifted their price objective on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a report on Monday, November 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Arbutus Biopharma presently has an average rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.